Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004554-30
    Sponsor's Protocol Code Number:LOXO-BTK-20020
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-09-01
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-004554-30
    A.3Full title of the trial
    A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
    Estudio en fase III, abierto y aleatorizado, de LOXO-305 en comparación con el ratamiento a elegir por el investigador entre idelalisib en combinación con rituximab o bendamustina en combinación con rituximab en la leucemia linfocítica crónica o linfoma linfocítico de células pequeñas, tratados previamente con inhibidores de la tirosina cinasa de Bruton (BTK, por sus siglas en inglés) (BRUIN CLL-321)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab
    Estudio en fase III para comparar LOXO-305 conla elección del investigador entre idelalisib en combinación con rituximab o bendamustina en combinación con rituximab
    A.4.1Sponsor's protocol code numberLOXO-BTK-20020
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04666038
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLoxo Oncology Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLoxo Oncology Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIQVIA RDS GmbH
    B.5.2Functional name of contact pointMedical and Scientific Services
    B.5.3 Address:
    B.5.3.1Street AddressUnterschweinstiege 2-14.
    B.5.3.2Town/ cityFrankfurt am Main
    B.5.3.3Post code60549
    B.5.3.4CountryGermany
    B.5.4Telephone number34 91916635000
    B.5.6E-mailmarialeticia.solari@iqvia.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLOXO-305
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot Available
    D.3.9.1CAS number 2101700-15-4
    D.3.9.2Current sponsor codeLOXO-305
    D.3.9.3Other descriptive nameLY3527727
    D.3.9.4EV Substance CodeSUB215610
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLOXO-305
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot Available
    D.3.9.1CAS number 2101700-15-4
    D.3.9.2Current sponsor codeLOXO-305
    D.3.9.3Other descriptive nameLY3527727
    D.3.9.4EV Substance CodeSUB215610
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Bendamustine Accord
    D.2.1.1.2Name of the Marketing Authorisation holderAccord Healthcare B.V.
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBendamustine Hydrochloride
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBENDAMUSTINE HYDROCHLORIDE
    D.3.9.1CAS number 3543-75-7
    D.3.9.4EV Substance CodeSUB00696MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Bendamustin cell pharm®
    D.2.1.1.2Name of the Marketing Authorisation holderCell pharm GmBH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBendamustine Hydrochloride
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBENDAMUSTINE HYDROCHLORIDE
    D.3.9.1CAS number 3543-75-7
    D.3.9.4EV Substance CodeSUB00696MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MabThera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRituximab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.4EV Substance CodeSUB12570MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MabThera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Pharma (Switzerland) AG, Basel
    D.2.1.2Country which granted the Marketing AuthorisationSwitzerland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRituximab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.4EV Substance CodeSUB12570MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Zydelig
    D.2.1.1.2Name of the Marketing Authorisation holderGilead Sciences Ireland UC
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIdelalisib
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIDELALISIB
    D.3.9.1CAS number 870281-82-6
    D.3.9.4EV Substance CodeSUB126168
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Zydelig
    D.2.1.1.2Name of the Marketing Authorisation holderGilead Sciences Ireland UC
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIdelalisib
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIDELALISIB
    D.3.9.1CAS number 870281-82-6
    D.3.9.4EV Substance CodeSUB126168
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Leucemia linfocítica crónica / Linfoma linfocítico de células pequeñas
    E.1.1.1Medical condition in easily understood language
    Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years.
    Leucemia linfocítica crónica / Linfoma linfocítico de células pequeñas es un tipo de cáncer que afecta a los glóbulos blancos y tiende a progresar lentamente durante muchos años.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10008976
    E.1.2Term Chronic lymphocytic leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) compared to investigator’s choice of idelalisib plus rituximab
    (IdelaR) or bendamustine plus rituximab (BR) (Arm B).
    Evaluar la supervivencia sin progresión (SSP) de LOXO-305 en monoterapia (grupoA) en comparación con la elección del investigador entre idelalisib en combinación con rituximab (IdelaR) o bendamustina en combinación con rituximab (BR) (grupoB).
    E.2.2Secondary objectives of the trial
    •To evaluate the effectiveness of Arm A compared to Arm B based on overall response rate (ORR) and time to event(s) outcomes
    •To evaluate the safety and tolerability of each treatment arm
    •To evaluate the effectiveness of Arm A compared to Arm B based on patient reported outcomes
    Evaluar la eficacia del grupo A en comparación con el grupo B, según la tasa de respuesta global (TRG) y el tiempo transcurrido hasta los resultados Evaluar la seguridad y la tolerabilidad de cada grupo de tratamiento Evaluar la eficacia del grupo A en comparación con el grupo B, de acuerdo con los resultados informadospor el paciente
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients are eligible to be included in the study only if all of the following criteria apply:
    Age
    1. Age 18 and older per local regulations at time of enrollment.
    Type of Patient and Disease Characteristics
    2. Confirmed diagnosis by redacted local laboratory report of CLL/SLL as defined by iwCLL 2018 criteria including the following:
    a) B cells coexpressing the surface antigen CD5 together with at least one B-cell antigen (CD19, CD20, CD23) and either κ or λ light-chain restricted.
    b) ≥ 5 × 109 B lymphocytes/L (5000/μL) in the peripheral blood. For SLL patients, history of ≥ 5 × 109 B lymphocytes/L (5000/μL) in the peripheral blood is allowed.
    c) Prolymphocytes may comprise ≤ 55% of blood lymphocytes.
    3. A requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy such that at least 1 of the following should be met:
    a) Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (such as hemoglobin < 10 g/dL) and/or thrombocytopenia (such as platelets ≤ 100 × 109/L).
    b) Massive (i.e., spleen edge ≥ 6 cm below the left costal margin) or progressive or symptomatic splenomegaly (> 13 cm).
    c) Massive nodes (i.e., ≥ 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
    d) Progressive lymphocytosis with an increase of > 50% over a 2-month period, or lymphocyte doubling time < 6 months. Factors contributing to lymphocytosis other than CLL/SLL (e.g., infections, steroid administration) should be excluded.
    e) Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids.
    f) Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine).
    g) Disease-related symptoms (also known as B-symptoms) as defined by any of the following:
    i) Unintentional weight loss ≥ 10% within the previous 6 months.
    ii) Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance scale 2 or worse; cannot work or unable to perform usual activities).
    iii) Fevers ≥ 100.5°F or 38.0°C for 2 or more weeks without evidence of infection.
    iv) Night sweats for ≥ 1 month without evidence of infection.
    4. Known 17p deletion status.
    5. Previously treated with a covalent BTK inhibitor, investigational or approved, and either alone or in combination with other agents. Patients may have received an unlimited number of lines of prior therapy.
    6. Eastern Cooperative Oncology Group (ECOG) 0-2.
    7. Must have adequate organ function, as defined below. These values must be met during the screening period as well as pre-dose on Cycle 1 Day 1 (C1D1).
    8. Patients are required the have had the following washout periods prior to planned C1D1:
    a) Targeted agents or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter
    b) Therapeutic monoclonal antibodies: 4 weeks
    c) Palliative limited field radiation: 7 days
    d) Broad field radiation (≥ 30% of bone marrow or whole brain radiotherapy): 28 days
    9. Prior treatment related AEs must have recovered to Grade ≤ 1 or pretreatment baseline with the exception of alopecia.
    Contraception
    10. Willingness of men and women of reproductive potential to observe conventional and highly effective or acceptable birth control methods for the duration of treatment and for 6 months following the last dose of study treatment or 12 months after the last dose of rituximab.
    Informed Consent
    11. Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    Other Inclusions
    12. Able to swallow oral study medication.
    13. Able to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
    Los pacientes serán aptos para la inscripción en el estudio solo si cumplen todos los criterios siguientes: Edad 1. Edad a partir de 18 años según la normativa local en el momento de la inscripción. Tipo de características de la enfermedad y del paciente 2. Diagnóstico confirmado mediante informe del laboratorio local redactado de LLC/LLP según se define en los criterios del iwCLL 2018, incluidos los
    siguientes: a) linfocitos B que coexpresan el antígeno de superficie CD5 junto con al menos un antígeno de linfocitos B (CD19, CD20, CD23) y restringido porcadenas ligeras # o #. b) #5 × 109 linfocitos B/l (5000/µl) en sangre periférica. Para los pacientes con LLP, se permiten antecedentes de #5 × 109 linfocitos B/l (5000/µl) en sangre periférica. c) Los prolinfocitos pueden abarcar #55 % de los
    linfocitos sanguíneos. 3. La necesidad de tratamiento debe ser coherente con los criterios del iwCLL 2018 para el inicio del tratamiento, por lo que debe cumplirse al menos 1 de los siguientes criterios: a) Indicios de insuficiencia medular progresiva, manifestada por el desarrollo o empeoramiento de anemia (como hemoglobina <10 g/dl) y/o trombocitopenia (como plaquetas #100 × 109/l). b) Esplenomegalia masiva
    (es decir, borde del bazo #6 cm por debajo del reborde costal izquierdo) o progresiva o sintomática (>13 cm). c) Ganglios masivos (es decir, #10 cm en el diámetro más largo) o linfadenopatía progresiva o sintomática. d) Linfocitosis progresiva con un aumento >50 % durante un periodo de 2 meses, o tiempo de duplicación de linfocitos <6 meses. Deben excluirse factores que contribuyen a la
    linfocitosis distintos de LLC/LLP (p. ej., infecciones, administración de esteroides).
    e) Complicaciones autoinmunitarias, incluida anemia o trombocitopenia, que no responden bien a los corticoesteroides. f) Afectación extraganglionar sintomática o funcional (p. ej., piel, riñón, pulmón, columna). g) Síntomas relacionados con la
    enfermedad (también conocidos como síntomas B) definidos por cualquiera de los
    siguientes: i) Pérdida de peso involuntaria #10 % en los 6 meses anteriores. ii) Fatiga importante (según escala del estado funcional del Grupo Oncológico Cooperativo del Este [Eastern Cooperative Oncology Group, ECOG] de 2 o peor;
    no puede trabajar o no puede realizar las actividades habituales). iii) Fiebre # 100,5°F o 38,0 °C durante 2 o más semanas sin indicios de infección. iv) Sudores nocturnos durante #1 mes sin indicios de infección. 4. Estado de deleción de 17p conocido. 5. Tratado previamente con un inhibidor covalente de BTK, en investigación o aprobado, ya sea solo o en combinación con otros fármacos. Los
    pacientes pueden haber recibido un número ilimitado de líneas de tratamiento previo. 6. Puntuación del Grupo Oncológico Cooperativo del Este (ECOG) 0-2. 7.Debe tener función orgánica adecuada, según la definición detallada más abajo
    Estos valores deben cumplirse durante el periodo de selección, así como antes de
    la dosis del día 1 del ciclo 1 (D1C1). 8. Se requiere que los pacientes hayan tenido los siguientes periodos de reposo farmacológico antes del D1C1 planificado: a)fármacos dirigidos o quimioterapia citotóxica: 5 semividas o 2 semanas, lo que sea
    más corto, b) Anticuerpos monoclonales para uso terapéutico: 4 semanas, c) Radiación de campo limitado: 7 días, d) Radiación de campo amplio (#30 % de la médula ósea o radioterapia holocraneal): 28 días 9. Los AA relacionados con el
    tratamiento previo deben haber remitido a grado #1 o al valor inicial previo al tratamiento, a excepción de la alopecia. Anticoncepción 10. Disposición de hombres y mujeres en edad fértil para utilizar métodos anticonceptivos convencionales y muy eficaces o aceptables durante el tratamiento y durante 6 meses después de la última dosis del tratamiento del estudio o 12 meses después de la última dosis de rituximab. Consentimiento informado 11. Estar dispuesto y ser capaz de dar su consentimiento informado firmado, lo que incluye el cumplimiento de los requisitos y restricciones enumerados en el formulario de consentimiento informado (FCI) y en este protocolo.
    Otros criterios de inclusión
    12. Capaz de tragar los medicamentos del estudio por vía oral. 13. Capaz de cumplir con el tratamiento ambulatorio, los controles analíticos y las visitas clínicas requeridas durante la participación en el estudio.
    E.4Principal exclusion criteria
    Patients are excluded from the study if any of the following criteria apply:
    Medical Conditions
    1. Known or suspected Richter’s transformation to diffuse large B cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin lymphoma at any time preceding enrollment.
    2. Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
    3. History of Grade ≥2 arrhythmia on prior covalent BTK inhibitor.
    4. Patients who experienced a major bleeding event on a prior BTK inhibitor.
    NOTE: major bleeding is defined as bleeding having one or more of the following features: life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2 g/dL; or bleeding in a critical area or organ (e.g. retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)
    5. Active second malignancy. Patients with treated second malignancy who are in remission with life expectancy > 2 years and with documented sponsor approval are eligible.
    Examples include:
    a) Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease.
    b) Adequately treated cervical carcinoma in situ without current evidence of disease.
    c) Localized (e.g., lymph node negative) breast cancer treated with curative intent with no evidence of active disease present for more than 3 years and receiving adjuvant hormonal therapy.
    d) Localized prostate cancer undergoing active surveillance.
    e) History of treated and cured Hodgkin's disease or NHL within 5 years from diagnosis.
    6. Major surgery, within 4 weeks of planned start of study treatment.
    7. History of or ongoing drug-induced pneumonitis.
    8. Ongoing drug-induced liver injury, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis and cirrhosis of the liver.
    9. History of allogeneic or autologous SCT or CAR-T therapy within the past 60 days
    10. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) not on a stable regimen and dose for at least 4 weeks prior to study enrollment
    11. Significant Cardiovascular disease defined as:
    a) Unstable angina or acute coronary syndrome within the past 2 months,
    b) History of myocardial infection within 3 months prior to planned start of LOXO-305,
    c) Documented LVEF by any method of ≤ 40% in the 12 months prior to planned start of LOXO-305,
    d) ≥ Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias
    12. Prolongation of the QT interval corrected (QTc) for heart rate using Fredericia’s Formula (QTcF) > 470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF > 470 msec on all 3 ECGs, during Screening.
    a) QTcF is calculated using Fredericia’s Formula (QTcF = QT/(RR^0.33)
    b) Correction of suspected drug-induced QTcF prolongation or prolongation due to electrolyte abnormalities can be attempted at the investigator’s discretion, and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation or electrolyte supplementation.
    c) Correction of QTc for underlying bundle branch block (BBB) permissible.
    13. Hepatitis B or hepatitis C testing indicating active/ongoing infection based on screening labs as defined as:
    a) Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are hepatitis B PCR positive will be excluded.
    b) Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.
    c) For optional crossover, repeat testing is not required.
    14. Known active cytomegalovirus (CMV) infection. Unknown or negative status eligible.
    15. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other clinically significant active disease process which in the opinion of the investigator and Medical Monitor may pose a risk for patient participation. Screening for chronic conditions is not required.
    16. Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count. Patients with unknown or negative status are eligible.
    17. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the oral administered study treatments.
    18. Ongoing inflammatory bowel disease.
    19. Prior exposure to non-covalent (reversible) BTK inhibitor.
    Lospctesseexcluyendelestudiosiseaplicaalgunodelossiguientescriterios:Patologías
    médicas1.Conocimientoosospechade1transformacióndeRichteralinfomadifusodecélulasBgrandesLDCBGleucemiaprolinfocíticaolinfomadeHodgkinencualquiermomentoprevioalainscripción.2Conocimientoosospechadeantecedentesdeafectacióndelsistemanerviosocentral
    (SNCLLC/LLP.3.Antecedentesdearritmiadegrado#2conuninhibidorcovalentedeBTKprevio.4.PctesqexperimentaronunepisodiohemorrágicograveconuninhibidordeBTKprevio.NOTA1hemorragiagravesedefinecomo1hemorragiaqtiene1omásdelassiguientescaracterísticashemorragiapotencialmentemortalconsignososíntomasdeafectaciónhemodinámicahemorragiaasociadaa1disminucióndelniveldehemoglobinadealmenos2g/dlohemorragiaen1zonauórganocríticop.ejhemorragiaretroperitonealintraarticularpericárdicaepiduralointracranealohemorragiaintramuscularconsíndrome
    compartimental)5.Segundaneoplasiamalignaactiva.Sonaptoslospctesconsegundaneoplasia maligna tratada
    qesténenremisióncon1esperanzadevida>2añosyconlaaprobacióndocumentadadelpromotor.Algunosejemplosson:aCáncerdepielno
    melanomatosoomelanomalentigomalignotratadosadecuadamentesinindiciosactualesdeenfermedad.bCarcinomacervicouterino
    insitutratadaadecuadamentesinindiciosactualesdeenfermedad.cCáncerdemamalocalizado(pejnegativo para ganglios linfáticos)tratadocon
    intencióncurativasinindiciosdeenfermedadactivapresentedurantemásde3añosyparaelqseestéadministrandohormonoterapiacomplementaria.d)Cáncerdepróstatalocalizadosometidoavigilanciaactiva.e)AntecedentesdeenfermedaddeHodgkintratadaycuradaoLNHenlos
    5añossiguientesaldiagnóstico.6Cirugíamayorenlas4semanaspreviasalinicioprevistodeltratamientodelestudio7Antecedentesdeneumonitisinducidaxfármacosoencurso.8Lesiónhepáticainducidaxfármacosencursocirrosisbiliarprimariaobstrucciónextrahepáticacausadacolelitiasisycirrosishepática.9AntecedentesdeTCMalógenooautólogootratamientoconCARTenlosúltimos60días8.Lesiónhepáticainducidaxfármacosencursocirrosisbiliarprimariaobstrucciónextrahepáticacausadaxcolelitiasisycirrosishepática9.AntecedentesdeTCMalógenooautólogootratamientoconCAR-Tenlosúltimos60días10.Citopeniaautoinmunitariaactivanocontrolada(p.ej.anemiahemolíticaautoinmunitaria[AHAI]púrpuratrombocitopénicaidiopática[PTI]qnoestérecibiendounrégimeny1dosisestablesdurantealmenos4semanasantesdelainscripciónenelestudio11Enfermedadcardiovascularimxtante
    definidacomoaAnginainestableosíndromecoronarioagudoenlosúltimos2meses,bAntecedentesdeinfecciónmiocárdicaenlos3mesespreviosalinicioprevistode LOXO-305 c)FEVI #40%enlos12mesespreviosalinicioprevistodeLOXO-305documentadaxcualquiermétodod)insuficienciacardíacacongrado#3segúnSistemadeclasificaciónfuncionalde la NYHAarritmiasnocontroladaso
    sintomáticas12ProlongacióndelintervaloQTcorregido (QTc)paralafrecuenciacardíacautilizandolafórmuladeFredericia (QTcF)
    >470msenalmenos2de 3ECGconsecutivosyQTcFmedio>470msenlos3ECGdurantelaselección.aElQTcFsecalculautilizandoafórmuladFredericia(QTcF=QT/(RR^0,33)bSepuedeintentarcorregirlaprolongacióndelQTcFinducidaxelfármacoolaprolongacióndebidoaanomalías
    electrolíticasadiscrecióndelinvestigadorysolosiesclínicamentesegurohacerloyaseaconlainterrupcióndelfármacocausanteocambioaotrofármacoqnoesté
    asociadoalaprolongacióndelQTcFoconsuplementaciónelectrolítica.c)CorreccióndelQTcpara
    bloqoderamaBRsubyacentepermisible.13PruebasdehepatitisBohepatitiCqindican1infección
    activa/encursosegúnlosanálisisdeseleccióndefinidoscomoa)VirusdehepatitisB(VHB)seexcluyealospctesconesultadopositivoenantígenode
    superficiedelvirusdelahepatitisB(HBsAg).Lospctesconresultadopositivoenanticuerposcontraelnúcleo
    delahepatitisB(anti-HBc)yresultadonegativoenHBsAgrequieren1evaluacióndelareacciónencadenadelapolimerasa(polymerasechainreactionPCR)delahepatitisBantesdelaaleatorización.SeexcluiráalospctesconPCRpositivaenhepatitisBb)VirusdelahepatitisCVHCpositivoenanticuerpos delahepatitisC.Sielresultadodeanticuerpos de la hepatitisC es positivoel pcte deberátenerunresultadonegativoparaácidoribonucleicoARNdelahepatitis Cantesdelaaleatorización.SeexcluiráalospctesconresultadopositivoparaARNdelahepatitisC.c)Paraelcruzadoopcionalnoesnecesario
    repetir la prueba.14.Infecciónactivaconocida x citomegalovirus(CMV)Conestadodesconocidoonegativosonaptos15Indiciosdeotra(s)afección(es)clínicamentesignificativasnocontroladaincluidasentreotrasinfecciónsistémicanocontrolada(víricabacterianaofúngica)uotroprocesodeenfermedad
    activaclínicamentesignificativaqenopinióndelinvestigadordelsupervisormédicopuedasuponerunriesgoparala
    participacióndelpaciente.Noesnecesaria1selecciónparalasenfermedadescrónicas.16Infecciónconocidaxelvirusdelainmunodeficienciahumana
    VIHindependientementedelrecuentodeCD4Lospctesconestadodesconocidoonegativosonaptos.17SíndromedemalabsorciónctivaclínicamentesignificativauotraafecciónqprobablementeafectealaabsorcióngastrointestinalGIdelostratamientosdelestudio administradosx
    víaoral.18.Enfermedadinflamatoriaintestinalencurso.19.Exposiciónpreviaauninhibidornocovalente(reversible)de BTK
    E.5 End points
    E.5.1Primary end point(s)
    Assessed by Independent Review Committee (IRC):
    • PFS per iwCLL 2018
    Evaluado por el comité de revisión independiente (CRI):
    SSP según el iwCLL 2018
    E.5.1.1Timepoint(s) of evaluation of this end point
    The time from the date of randomization until PD or death from any cause, whichever occurs first
    El tiempo desde la fecha de aleatorización hasta la PE o la muerte por cualquier
    causa, lo que ocurra primero
    E.5.2Secondary end point(s)
    • Assessed by investigator:
    - PFS per iwCLL 2018 criteria
    - Overall survival (OS)
    - Time to next treatment (TTNT), defined as time from the date of randomization to the date of the next systemic anticancer therapy for CLL/SLL
    (Section 9 for full definition).
    - Time to treatment failure (TTF), defined as a composite endpoint measuring time from randomization to time when discontinuation criteria
    met (Section 7).
    - Event free survival (EFS) defined as the time from date of randomization to the date of PD or start of new treatment for CLL/SLL or discontinuation from trial due to toxicity or death, whichever occurs first.
    • Assessed by investigator and IRC:
    - ORR
    - Duration of response (DOR)
    • Including, but not limited to, serious adverse events (SAEs), adverse events (AEs), deaths and clinical laboratory abnormalities per National Cancer Institute Common Terminology Criteria in Adverse Events v5.0 (NCI CTCAE v5.0)
    • Patient reported outcomes of:
    - Time to worsening (TTW) of CLL/SLL-related symptoms
    - TTW of physical functioning
    Evaluado por el investigador : SSP según los criterios del iwCLL 2018 –
    Supervivencia general (SG) Tiempo hasta el siguiente tratamiento (THST), definido como el tiempo transcurrido desde la fecha de aleatorización hasta la fecha del siguiente tratamiento antineoplásico sistémico para la LLC/LLP (ver sección 9 para
    la definición completa).
    - Tiempo hasta el fracaso terapéutico (TFT), definido como
    un criterio de valoración compuesto que mide el tiempo desde la aleatorización hasta el momento en que se cumplen los criterios de interrupción (sección 7).
    Supervivencia libre de acontecimientos (EFS) definida como el tiempo desde la
    fecha de aleatorización hasta la fecha de la PE o el inicio de un nuevo tratamiento
    para la LLC/LLP o la interrupción del ensayo debido a toxicidad o muerte, lo que ocurra primero.
    • Evaluado por el investigador y el CRI:
    - TRG - Duración de la respuesta (DR)
    • Incluidos, entre otros, acontecimientos adversos graves (AAG), acontecimientos adversos (AA), muertes y anomalías analíticas clínicas según los
    Criterios terminológicos comunes para acontecimientos adversos del Instituto Nacional del Cáncer de EE. UU. v5.0 Resultados comunicados por el paciente de: -
    Tiempo hasta el empeoramiento (ThE) de los síntomas relacionados con la
    LLC/LLP - ThE del funcionamiento físico
    E.5.2.1Timepoint(s) of evaluation of this end point
    PFS - The time from the date of randomization until PD or death from any cause, whichever occurs first
    ORR - achieve a BOR of CR, PR
    DOR - The time from the date of the first documented response of CR, CRi, nPR, or PR to the earlier of the documentation of definitive PD or death from any cause
    OS - The time from randomization until death from any cause.
    TTNT - The Time from the date of randomization to the date of the initiation of the next non-protocol-specified therapy for CLL/SLL or death due to any cause, whichever occurred first
    TTF - A composite endpoint measuring time from randomization to discontinuation of treatment for any reason
    EFS - date of PD or start of new treatment for CLL/SLL or discontinuation from study due to toxicity or death, whichever occurs first
    SSP-El tiempo desdelafecha de aleatorizaciónhastala PE olamuerteporcualquiercausalo que ocurra primero. TRG: alcanzar una MRG
    deRC,DR de laRP: el tiempodesdelafecha delaprimerarespuestadocumentada
    deRCRCi,RPg o RP hasta la documentación más tempranadePEconfirmadaomuerte porcualquiercausa.SG:el tiempotranscurrido desde la
    aleatorización hasta la muerte por cualquier causa.THSTel tiempo desde la fechade aleatorizaciónhastalafechadel
    iniciodelsiguientetratamientonoespecificadoenelprotocoloparalaLLC/LLPomuertepor cualquiercausaloqueocurra
    primero.TFT:uncriteriodevaloracióncompuestoquemideeltiempodesdelaaleatorizaciónhastala interrupcióndeltratamientoporcualquiermotivo.EFS:fechadela PEoiniciodeunnuevotratamientoparalaLLC/LLPointerrupcióndelestudio
    debidoatoxicidadomuerteloqueocurraprimero
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA103
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    China
    Israel
    Japan
    Korea, Republic of
    New Zealand
    Russian Federation
    Singapore
    Taiwan
    United States
    Austria
    Belgium
    Croatia
    Denmark
    Finland
    France
    Germany
    Hungary
    Ireland
    Italy
    Netherlands
    Norway
    Poland
    Portugal
    Romania
    Spain
    Sweden
    Switzerland
    United Kingdom
    Czechia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last visit of the last participant in the study or last scheduled procedure shown in the Schedule of Assessments (SoA) for the last participant in the trial globally, which is estimated at approximately 36.5 months from the first patient randomized to allow 12.5 months recruitment and 24 months of follow-up.
    El final del estudio se define como la fecha de la última visita del último participante en el estudio o el último procedimiento programado que se realiza según la tabla de procedimientos para el último participante en el ensayo a nivel mundial, que se estima en aproximadamente 36,5 meses desde el primer paciente randomizado
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 75
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 175
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 134
    F.4.2.2In the whole clinical trial 250
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    It is anticipated that a patient on this study will receive study treatment with LOXO-305 until the patient is able to obtain commercially available LOXO-305 in their respective country, if the patient does not meet criteria requiring discontinuation of treatment, and the patient’s participation in the study has not ended.
    Se anticipa que un paciente en este estudio recibirá el tratamiento del estudio con LOXO-305 hasta que el paciente pueda obtener LOXO-305 disponible
    comercialmente en su país respectivo, si el paciente no cumple con los criterios que requieren la interrupción del tratamiento y la participación del paciente en el estudio
    no ha terminado.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-18
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:00:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA